Oxford Textbook of Neurohaematology

Cover
Series
Title
Copyright
Contents
Foreword
Preface
Editors
Contributors
Abbreviations
SECTION 1 Neurological conditions associated with malignant haematological diseases
	1 Primary CNS diffuse large B-​cell lymphoma
	2 Immunodeficiency-​associated primary CNS diffuse large B-​cell lymphoma
	3 Vitreoretinal lymphoma
	4 Rare primary CNS lymphomas
	5 Histiocytic tumours of the central nervous system
	6 Neurological complications of myeloid malignancies
	7 Neurological complications of lymphoid malignancies
Section 2NayakSECTION 2Neurological complications of treatments used in the management of haematological malignancies
	8 Neurological complications of medical therapies in haematological malignancies
		Introduction
		Direct neurotoxicity
			General aspects
	9 Neurological complications of cell therapies in haematological malignancies
		Introduction
		Clinical approach
		Indications for stem cell transplantation (with levels of evidence I, II, and III)
		Neurological complications in theconditioning phase
			Drugs
			Table 9.2 Timeline of neurological complications with haematological stem cell transplantation
			Table 9.3 Neurological complications associated with drugs commonly used in haematological stem cell transplantation
			Posterior reversible encephalopathy syndrome
			Complications during pancytopenia
	10 Neurological complications of radiation therapies in haematological malignancies
SECTION 3 Neurological conditions and complications associated with non-​malignant haematological disorders
	11 Neurological complications of red blood cell disorders
		Introduction
		Hypoproliferative anaemias
			Neurological complications of iron deficiency
				Restless legs syndrome
				Treatment and outcomes
				Neurocognitive symptoms
			Neurological complications of cobalamin deficiency
				Frequency and risk factors
				Aetiology and pathogenesis
			Neurological complications of folate deficiency
				Frequency and risk factors
				Diagnostic testing
				Treatment and outcomes
		Disorders of haemoglobin
			Neurological complications of sickle cell disease
				Frequency and risk factors
				Aetiology and pathogenesis
	12 Neurological complications of platelet disorders and disorders of coagulation
		Introduction
		Haemophilia
			Epidemiology, frequency, and risk factors
			Diagnosis
				Figure 12.1 Proposed screening and diagnostic algorithm for haemophilias and acquired haemophilia.
			Prevention and treatment
				Table 12.2 Selected target factor activity levels per injury
			Bypassing agents
		Thrombocytopenias
			Immune thrombocytopenia (formerlyidiopathic thrombocytopenic purpura)
			Diagnosis
			Prevention and treatment
				Table 12.3 First- and second- line treatment for immunethrombocytopenia
			Outcome
		Thrombotic thrombocytopenic purpura
			Table 12.4 Common neurological manifestationsof thrombotic thrombocytopenic purpura
			Epidemiology, frequency, and risk factors
			Aetiology/ pathogenesis
			Clinical presentation
			Prevention and treatment
		Heparin- induced thrombocytopenia
			Epidemiology, frequency, and risk factors
				Figure 12.2 The pathogenesis of heparin- induced thrombocytopenia (HIT) is characterized by gaps in our knowledge. Genomic biomarkers havethe potential to answer critical questions at every stage of HIT pathogenesis, including the predisposing immunogen, the cellular source of antibodies,the identification of pathogenic immunoglobin G (IgG) antibodies, and the mechanisms of thrombosis. Similarly, the clinical progression of a patientwho will eventually develop HIT is characterized by various unmet clinical needs. Genomic biomarkers have the potential to meet many of the unmetclinical needs for HIT, including limitations in the clinical utility of platelet count monitoring, PF4/ heparin antibody testing, functional assay testing, andlimited treatment options. APC, antigen- presenting cell; FcγRIIA, platelet FcγRIIa receptor; HIPA, heparin- induced platelet aggregation; HIT, heparininducedthrombocytopenia; IVIG, intravenous immunoglobulin; NOAC, novel oral anticoagulant; PF4, platelet factor 4; SRA, serotonin release assay.
			Diagnosis
			Figure 12.3 Algorithm for management of heparin- induced thrombocytopenia (HIT).
			Table 12.5 The 4T score
			Prevention and treatment
		Disseminated intravascular coagulation
	13 Neurological complications of white blood cell disorders
		Hyperviscosity syndrome and the nervous system
			Introduction
			Epidemiology
			Pathogenesis
				Viscosity
			Clinical presentation of hyperviscosity
			Treatment of hyperviscosity syndrome
				Plasmapheresis
				Chemotherapy
		AL amyloidosis and the nervous system
			Aetiology/ pathogenesis
			Clinical presentation
			CASE STUDY 13.1 Signs for amyloidosis: fatigue,renal dysfunction, and development of neuropathy
			CASE STUDY 13.2 Local amyloid can mimiccranial nerve lesions
			CASE STUDY 13.3 Amyloidoma of theperipheral nerve
			Central nervous system
			Giant cell arteritis
			Prevention and treatment
		Conclusions
Index